# Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

> **NCT00089609** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 73 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Thalidomide
- **DRUG:** Prednisone
- **BIOLOGICAL:** bevacizumab
- **GENETIC:** polymorphism analysis
- **OTHER:** immunoenzyme technique
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00089609
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04-19
- **Primary completion:** 2011-12-31
- **Final completion:** 2018-01-09
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2018-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00089609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00089609, "Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00089609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*